MyGenera™ biotechnology is applicable to all diseases in which it is possible to intervene by silencing the pathological gene or genes responsible for the illness.
The innovation of
Development of gene-specific oligonucleotide drugs
Significantly shorter candidate drug molecule identification times compared to conventional methods.
Improved drug efficacy
Reduced or absent therapy toxicity
Development of gene-specific oligonucleotide drugs
Gene-specific therapies and their mechanism of action
The new class of gene-specific oligonucleotide drugs is characterized by a short sequence of modified DNA that acts on a single pathological target gene.
01
The gene-specific molecule
Target gene (two copies per cell)
The gene-specific molecule is an oligonucleotide that inhibits the activity of a target gene (by blocking mRNA transcription).
02
The mechanism
mRNA (thousands of copies)
The gene-specific oligonucleotide acts by selectively and strongly binding to a strand of the complementary DNA sequence contained in the target gene. The binding occurs on a strand of the open structure of the active target gene’s DNA, thereby blocking its transcription.
03
Applications
Protein (thousands of copies)
MyGenera™ biotechnology is applicable to all diseases in which it is possible to intervene by silencing the pathological gene or genes responsible for the illness.
English 
Italian